Humans' Consumption Patterns and Motivations: Beyond Sensory Delights Amplified

Humans' Consumption Patterns and Motivations: Beyond Sensory Delights Amplified

In a significant turn of events, the use of GLP-1 agonists such as Ozempic, Wegovy, and Mounjaro is reshaping consumer behavior and the retail landscape. These weight loss drugs, which suppress appetite, are leading to a decrease in spending on groceries, fast food, snacks, and indulgent foods.

According to data from GWI, one in eight people in the US currently takes or has taken GLP-1 agonists. This shift in consumer behavior is not limited to the US, with four in 100 households in the UK now including at least one GLP-1 user. The number of users is estimated to increase by 20% over the next five years.

The food retail sector is adapting to this change by repositioning products toward "GLP-1 friendly" attributes like high protein, low calorie, and gut-friendly ingredients. Studies show that GLP-1 users reduce spending on groceries by about 6%, fast food by 9%, and snacks by 11%. Retailers report increased sales in these segments, such as a 20% rise in high-protein meal kits after rebranding.

Brands targeting GLP-1 users should consider reformulating products to emphasize functional nutrition (high protein, fiber, low sugar) and smaller portion sizes. They should also reposition marketing messages away from indulgence and cravings toward health, satiety, and metabolic benefits. Innovation in product categories gaining traction among GLP-1 users, such as plant-based protein snacks and meal replacements, is also crucial.

However, brands must also monitor regulatory and health concerns, including the risk of side effects and unsupervised use-related complications, to responsibly tailor communications and product development.

The impact of GLP-1 drugs extends beyond the food industry. There has been a 295% increase in dating and a 200% growth in people seeking therapy to cope with changes caused by GLP-1 drugs.

Nestlé has already capitalized on this trend, introducing a new food line called Vital Pursuit in May 2024, designed specifically for people taking GLP-1 agonists. Havas Health Network opened a consultancy earlier this year to help brands adapt to and take advantage of the effects of weight-loss drugs.

Industries may see a ripple effect from the increased use of GLP-1 drugs, but brands should not rush in blindly. Shauna Moran, data journalist at GWI, advises brands to consider whether current or potential GLP-1 users make up a meaningful slice of their customer base before making strategic changes.

Interestingly, breakfast cereal brands may not see as much success with GLP-1-friendly labels as other product categories. GWI's data suggests that 18% of GLP-1 users have 'spotted negative side effects', which could potentially slow the trend's growth.

In conclusion, GLP-1 drugs are not just helping people lose weight, but also changing their consumption habits and affecting other categories. Brands must adapt to these changes to remain competitive and meet the evolving needs of their consumers.

[1] GWI (2023). GLP-1 Agonists and Their Impact on Consumer Behavior. [2] Moran, S. (2023). The Ripple Effect of GLP-1 Agonists on Industries. [3] Nestlé (2024). Introducing Vital Pursuit: A Food Line for GLP-1 Agonist Users. [4] Havas Health Network (2023). Navigating the Effects of Weight-Loss Drugs on Brands.

1. The increased use of GLP-1 agonists is reshaping consumer behavior by leading to reduced spending on groceries, fast food, snacks, and indulgent foods.
2. GWI reports that the shift in consumer behavior is not limited to the US and UK, with the number of GLP-1 users estimated to grow by 20% over the next five years.
3. The food retail sector is adapting to this change by focusing on "GLP-1 friendly" products with attributes like high protein, low calorie, and gut-friendly ingredients.
4. Brands should consider reformulating products to emphasize functional nutrition and smaller portion sizes, while also repositioning marketing messages toward health, satiety, and metabolic benefits.
5. GLP-1 drugs have a broader impact, with a 295% increase in dating and a 200% growth in people seeking therapy to cope with changes caused by GLP-1 drugs.
6. Industries like food, media, health-and-wellness, and finance may see a ripple effect from the increased use of GLP-1 drugs, and brands must adapt to remain competitive and meet the evolving needs of their consumers.
7. Brands should consider whether GLP-1 users make up a meaningful portion of their customer base before making strategic changes, and monitor regulatory and health concerns when developing and communicating their products.

Read also: